AptarGroup : Optimizing Your Pre-Clinical Discovery in Pulmonary and Nasal Drug Development
December 16, 2021 at 12:49 pm EST
Share
Join this webinar to discover more about these scientific guidelines and how Aptar Pharma's innovative devices for non-clinical research can meet unmet pharmaceutical needs and advance your molecule from formulation to patient. One new solution, PADA (Powder Administration Device for Animals), helps early phase pulmonary research, by enabling precise, rapid and efficient administration of a powder directly to the lungs of mice.
Register now for Aptar Pharma's free webinar on February 15, 2022:
Register for 9am London Session
Register for 3:30pm London Session
Attachments
Original Link
Original Document
Permalink
Disclaimer
AptarGroup Inc. published this content on 16 December 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 16 December 2021 17:48:04 UTC.
AptarGroup, Inc. is engaged in designing and manufacturing of drug and consumer product dosing, dispensing and protection technologies. The Company serves various end markets, including pharmaceutical, beauty, food, beverage, personal care and home care. The Company operates through three segments: Aptar Pharma, Aptar Beauty and Aptar Closures. Aptar Pharma segment supplies nasal drug delivery spray pumps and metered dose inhaler valves (MDIs) to the pharmaceutical and healthcare markets worldwide and supplies elastomer for injectable primary packaging components worldwide. The segment also provides services designed to accelerate and de-risk the development and regulatory approvals of drugs using drug delivery devices. The Aptar Beauty segment sells a variety of pumps, airless systems and valves to the fragrance, color cosmetics, facial skincare, personal care and home care markets. Aptar Closures segment primarily sells dispensing closures.
APTARGROUP, INC. 
